Valion Bio Terminates CEO, Appoints COO, and Secures $3M from Activist Investor
VBIO is trading near its 52-week low of $0.159 (7.7% above the low) on elevated volume (29× avg).
Summary
Valion Bio terminated its CEO, appointed a COO, and secured $3 million in funding from activist investor 3i, LP, contingent on governance changes and a 10-year revenue royalty.
Key Events · Executive and Board Changes · VBIO
-
CEO Terminated
Michael K. Handley was terminated as CEO effective August 16, 2026, following activist investor 3i, LP's demand for his removal.
-
COO Appointed
Lisa Wolf, currently CFO, was appointed Chief Operating Officer effective August 16, 2026, with no change to her existing employment agreement.
-
Reverse Split Approved
Stockholders approved a reverse stock split at a ratio between 1-for-5 and 1-for-50, with the board authorized to determine the exact ratio within 12 months.
-
$3M Funding from 3i
3i, LP agreed to purchase $1.5 million of Series B Preferred Stock and warrants on August 17, 2026, with a second $1.5 million tranche expected by August 24, 2026, contingent on governance changes.
Analysis · VBIO · Life Sciences
Valion Bio terminated CEO Michael Handley effective August 16, 2026, fulfilling a key demand from activist investor 3i, LP. In exchange, 3i agreed to purchase $1.5 million of Series B Preferred Stock and warrants immediately, with a second $1.5 million tranche expected by August 24, 2026. The company also granted 3i and other Series C purchasers a 10-year royalty of 5% of Velocity Bioworks' gross revenue. Stockholders approved a reverse stock split ratio of 1-for-5 to 1-for-50, giving the board discretion to execute within 12 months. These actions address the going-concern risk and Nasdaq delisting threat, but the royalty agreement and preferred stock issuance add significant dilution and future cash obligations.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $0.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $791.2K. The 52-week trading range was $0.16 to $5.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.